Panobinostat (original) (raw)
Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States.
| Property | Value |
|---|---|
| dbo:abstract | El panobinostat (LBH-589) es un fármaco experimental desarrollado por Novartis para el tratamiento del cáncer. Desde diciembre de 2008, se está probando su eficacia contra el (LCCT), leucemia mieloide crónica, síndrome mielodisplásico, cáncer de seno, cáncer de próstata y otros tipos de enfermedades en varios ensayos clínicos de fase II y III, por ejemplo un estudio fase III para LCCT. El panobinostat ha demostrado actuar sinérgicamente con el sirolimus matando células pancreáticas cancerígenas en pruebas de laboratorio en la clínica Mayo. En este estudio, los investigadores encontraron que esta combinación destruyó hasta el 65 por ciento de células pancreáticas tumorales cultivadas. El hallazgo es importante debido a que las tres líneas celulares estudiadas eran resistentes a los efectos de la quimioterapia, como lo son la mayor parte de los tumores pancreáticos. Actualmente ya comercializado en EE. UU., y recientemente, Novartis® ha recibido la aprobación de la U.E. para Farydak®, el primer anticancerígeno de su clase aprobado para pacientes con múltiples mielomas. (es) Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States. (en) パノビノスタット（Panobinostat）は多発性骨髄腫の治療に用いられるヒドロキサム酸誘導体である。非選択的(DAC阻害薬)の一つである。商品名ファリーダック、ノバルティスファーマが製造販売。開発コードLBH-589。 (ja) Panobinostat (LBH-589) é um fármaco em testes que poderá ser utilizado em casos de câncer. Trata-se de um inibidor potente de HDAC (histone deacetylase). É desenvolvido pela Novartis e desde 2008 está sendo testado em casos de linfoma cutâneo de células T, leucemia mieloide crônica, câncer de mama e próstata e outros tipos severos de câncer. (pt) |
| dbo:alternativeName | Farydak (en) |
| dbo:bioavailability | 21.000000 (xsd:float) |
| dbo:casNumber | 404950-80-7 |
| dbo:chEBI | 85990 |
| dbo:drugbank | DB06603 |
| dbo:fdaUniiCode | 9647FM7Y3Z |
| dbo:kegg | D10319 |
| dbo:pubchem | 6918837 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Panobinostat.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/panobinostat |
| dbo:wikiPageID | 20845241 (xsd:integer) |
| dbo:wikiPageLength | 15543 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1121457634 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Blood_plasma dbr:Bortezomib dbr:Breast_cancer dbc:Novartis_brands dbr:Hodgkin's_Lymphoma dbr:In_vitro dbc:Tryptamines dbr:Mayo_Clinic dbr:Nausea dbr:Oral_administration dbr:Chronic_myelomonocytic_leukemia dbr:Glioma dbr:Apoptosis dbr:Lymphopenia dbr:Sirolimus dbr:Clinical_trial dbr:Prostate_cancer dbr:Pancytopenia dbr:G2-M_DNA_damage_checkpoint dbr:Fatigue_(medical) dbc:Histone_deacetylase_inhibitors dbc:Orphan_drugs dbr:Cutaneous_T_cell_lymphoma dbr:Faeces dbr:Glucuronidation dbr:Histone_deacetylase_inhibitor dbr:Histone_deacetylase dbr:Hydroxamic_acid dbc:Cancer_treatments dbc:Hydroxamic_acids dbr:Bioavailability dbr:Biological_half-life dbr:Survival_of_motor_neuron dbr:Dexamethasone dbr:Diarrhoea dbr:Diffuse_large_B-cell_lymphoma dbr:CYP2C19 dbr:CYP2D6 dbr:CYP3A dbr:CYP3A4 dbr:Spinal_muscular_atrophy dbr:Metabolised dbr:Refractory_disease dbr:Medication dbr:Neutropenia dbr:Oxidation dbr:Immunomodulatory_drug dbr:Thrombocytopenia dbr:Leucopenia dbr:Triple_negative_breast_cancer dbr:Anaemia dbr:First-pass_effect dbr:Highly_active_antiretroviral_therapy dbr:Myelodysplastic_syndromes |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | XH03 (en) |
| dbp:bioavailability | 21.0 (dbd:perCent) |
| dbp:c | 21 (xsd:integer) |
| dbp:casNumber | 404950 (xsd:integer) |
| dbp:chebi | 85990 (xsd:integer) |
| dbp:chemspiderid | 5294028 (xsd:integer) |
| dbp:dailymedid | Panobinostat (en) |
| dbp:drugbank | DB06603 (en) |
| dbp:eliminationHalfLife | 133200.0 (dbd:second) |
| dbp:excretion | Fecal , renal (en) |
| dbp:h | 23 (xsd:integer) |
| dbp:iupacName | -N-hydroxy-3-[4-phenyl]acrylamide (en) |
| dbp:iupharLigand | 7489 (xsd:integer) |
| dbp:kegg | D10319 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalStatus | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:metabolism | dbr:CYP2C19 dbr:CYP2D6 dbr:CYP3A |
| dbp:n | 3 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:proteinBound | 90.0 (dbd:perCent) |
| dbp:pubchem | 6918837 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | O=C\C=C\c1cccCNCCc3c2ccccc2[nH]c3C (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | FPOHNWQLNRZRFC-ZHACJKMWSA-N (en) |
| dbp:synonyms | LBH-589 (en) |
| dbp:tradename | Farydak (en) |
| dbp:unii | 9647 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 455315413 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:width | 275 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:As_of dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Rp dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Drugs.com dbt:Intracellular_chemotherapeutic_agents dbt:HDAC_inhibitors |
| dct:subject | dbc:Novartis_brands dbc:Tryptamines dbc:Histone_deacetylase_inhibitors dbc:Orphan_drugs dbc:Cancer_treatments dbc:Hydroxamic_acids |
| gold:hypernym | dbr:Drug |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:Antineoplastic102722458 yago:CausalAgent100007347 yago:CytotoxicDrug103157987 yago:Drug103247620 yago:Inhibitor114724436 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 yago:WikicatHistoneDeacetylaseInhibitors dbo:Drug yago:Substance100020090 yago:WikicatExperimentalCancerDrugs umbel-rc:DrugProduct |
| rdfs:comment | Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States. (en) パノビノスタット（Panobinostat）は多発性骨髄腫の治療に用いられるヒドロキサム酸誘導体である。非選択的(DAC阻害薬)の一つである。商品名ファリーダック、ノバルティスファーマが製造販売。開発コードLBH-589。 (ja) Panobinostat (LBH-589) é um fármaco em testes que poderá ser utilizado em casos de câncer. Trata-se de um inibidor potente de HDAC (histone deacetylase). É desenvolvido pela Novartis e desde 2008 está sendo testado em casos de linfoma cutâneo de células T, leucemia mieloide crônica, câncer de mama e próstata e outros tipos severos de câncer. (pt) El panobinostat (LBH-589) es un fármaco experimental desarrollado por Novartis para el tratamiento del cáncer. Desde diciembre de 2008, se está probando su eficacia contra el (LCCT), leucemia mieloide crónica, síndrome mielodisplásico, cáncer de seno, cáncer de próstata y otros tipos de enfermedades en varios ensayos clínicos de fase II y III, por ejemplo un estudio fase III para LCCT. Actualmente ya comercializado en EE. UU., y recientemente, Novartis® ha recibido la aprobación de la U.E. para Farydak®, el primer anticancerígeno de su clase aprobado para pacientes con múltiples mielomas. (es) |
| rdfs:label | Panobinostat (es) パノビノスタット (ja) Panobinostat (en) Panobinostat (pt) |
| owl:sameAs | freebase:Panobinostat yago-res:Panobinostat wikidata:Panobinostat dbpedia-es:Panobinostat dbpedia-fa:Panobinostat dbpedia-ja:Panobinostat http://lt.dbpedia.org/resource/Panobinostatas dbpedia-pt:Panobinostat dbpedia-ro:Panobinostat dbpedia-sh:Panobinostat dbpedia-sr:Panobinostat dbpedia-vi:Panobinostat https://global.dbpedia.org/id/4tAia |
| prov:wasDerivedFrom | wikipedia-en:Panobinostat?oldid=1121457634&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Panobinostat.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Panobinostat |
| is dbo:wikiPageRedirects of | dbr:LBH-589 dbr:Faridak dbr:Farydak dbr:ATC_code_L01XX42 dbr:ATCvet_code_QL01XX42 dbr:Panobinostat_lactate dbr:Panobinostat_lactate_anhydrous |
| is dbo:wikiPageWikiLink of | dbr:List_of_antineoplastic_agents dbr:Vorinostat dbr:LBH-589 dbr:Multiple_myeloma dbr:Lung_cancer dbr:Faridak dbr:Farydak dbr:Karin_Briner dbr:Chromatin_remodeling dbr:Histone_deacetylase_inhibitor dbr:ATC_code_L01XX42 dbr:ATCvet_code_QL01XX42 dbr:Hydroxamic_acid dbr:ATC_code_L01 dbr:C21H23N3O2 dbr:CCDC92 dbr:Spinal_muscular_atrophy dbr:Panobinostat_lactate dbr:Panobinostat_lactate_anhydrous dbr:Michelle_Monje dbr:Cancer_epigenetics dbr:Thrombocytopenia |
| is foaf:primaryTopic of | wikipedia-en:Panobinostat |
